Effects of chronic Clozapine administration on apolipoprotein D levels and on functional recovery following experimental stroke

Brain Research

Volumn 1321, Issue , 2010, Pages 152-163

  Ruscher, Karsten ^a   Erickson, Agnes ^a   Kuric, Enida ^a   Inácio, Ana R ^a   Wieloch, Tadeusz ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Apolipoprotein D; Clozapine; Functional recovery; Ischemia; Peri infarct area; Stroke

Indexed keywords

APOLIPOPROTEIN D; CLOZAPINE; GLIAL FIBRILLARY ACIDIC PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC DRUG ADMINISTRATION; CONVALESCENCE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME;

ANIMALS; APOLIPOPROTEINS D; BLOTTING, WESTERN; CLOZAPINE; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICROSCOPY, CONFOCAL; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; STROKE;

RATTUS;

EID: 77549084949     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.01.024     Document Type: Article

References (48)

1. Ahnaou A., Megens A.A., and Drinkenburg W.H. The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology 48 (2003) 47-54
2. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., and Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9 (1993) 117-124
3. Boyles J.K., Notterpek L.M., and Anderson L.J. Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I. J. Biol. Chem. 265 (1990) 17805-17815
4. Carmichael S.T. Themes and strategies for studying the biology of stroke recovery in the poststroke epoch. Stroke 39 (2008) 1380-1388
5. Choc M.G., Lehr R.G., Hsuan F., Honigfeld G., Smith H.T., Borison R., and Volavka J. Multiple-dose pharmacokinetics of clozapine in patients. Pharm. Res. 4 (1987) 402-405
6. Cramer S.C. Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Ann. Neurol. 63 (2008) 272-287
7. Critchlow H.M., Maycox P.R., Skepper J.N., and Krylova O. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol. Cell. Neurosci. 32 (2006) 356-365
8. Dancause N., Barbay S., Frost S.B., Plautz E.J., Chen D., Zoubina E.V., Stowe A.M., and Nudo R.J. Extensive cortical rewiring after brain injury. J. Neurosci. 25 (2005) 10167-10179
9. Denney D., and Stevens J.R. Clozapine and seizures. Biol. Psychiatry 37 (1995) 427-433
10. Fassbender K., Rossol S., Kammer T., Daffertshofer M., Wirth S., Dollman M., and Hennerici M. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neurol. Sci. 122 (1994) 135-139
11. Gemperle A.Y., Enz A., Pozza M.F., Luthi A., and Olpe H.R. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 117 (2003) 681-695
12. Goldstein L.B., and Bullman S. Differential effects of haloperidol and clozapine on motor recovery after sensorimotor cortex injury in rats. Neurorehabil. Neural Repair 16 (2002) 321-325
13. Goudie A.J., Smith J.A., Robertson A., and Cavanagh C. Clozapine as a drug of dependence. Psychopharmacology (Berl) 142 (1999) 369-374
14. Katsman D., Zheng J., Spinelli K., and Carmichael S.T. Tissue microenvironments within functional cortical subdivisions adjacent to focal stroke. J. Cereb. Blood Flow Metab. 23 (2003) 997-1009
15. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 58 (2002) 1-10
16. Khan M.M., Parikh V.V., and Mahadik S.P. Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. J. Neurochem. 86 (2003) 1089-1100
17. Kline A.E., Hoffman A.N., Cheng J.P., Zafonte R.D., and Massucci J.L. Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. Neurosci. Lett. 448 (2008) 263-267
18. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., Hinze-Selch D., Kraus T., Dittmann R.W., and Pollmacher T. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 34 (2009) 118-128
19. Komitova M., Perfilieva E., Mattsson B., Eriksson P.S., and Johansson B.B. Enriched environment after focal cortical ischemia enhances the generation of astroglia and NG2 positive polydendrocytes in adult rat neocortex. Exp. Neurol. 199 (2006) 113-121
20. Kosacka J., Gericke M., Nowicki M., Kacza J., Borlak J., and Spanel-Borowski K. Apolipoproteins D and E3 exert neurotrophic and synaptogenic effects in dorsal root ganglion cell cultures. Neuroscience 162 (2009) 282-291
21. Macleod M.R., Fisher M., O'Collins V., Sena E.S., Dirnagl U., Bath P.M., Buchan A., van der Worp H.B., Traystman R., Minematsu K., Donnan G.A., and Howells D.W. Good laboratory practice: preventing introduction of bias at the bench. Stroke 40 (2009) e50-e52
22. Mahadik S.P., Khan M.M., Evans D.R., and Parikh V.V. Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome. Schizophr. Res. 58 (2002) 55-62
23. Mead A., Li M., and Kapur S. Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. Pharmacol. Biochem. Behav. 90 (2008) 551-562
24. Oerther S., and Ahlenius S. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat. J. Pharmacol. Exp. Ther. 292 (2000) 731-736
25. Ohlsson A.L., and Johansson B.B. Environment influences functional outcome of cerebral infarction in rats. Stroke 26 (1995) 644-649
26. Ong W.Y., He Y., Suresh S., and Patel S.C. Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus. Neuroscience 79 (1997) 359-367
27. Paine T.A., and Carlezon Jr. W.A. Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. Neuropharmacology 56 (2009) 788-797
28. Rickhag M., Wieloch T., Gido G., Elmer E., Krogh M., Murray J., Lohr S., Bitter H., Chin D.J., von Schack D., Shamloo M., and Nikolich K. Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of genes in surviving tissue. J. Neurochem. 96 (2006) 14-29
29. Rickhag M., Deierborg T., Patel S., Ruscher K., and Wieloch T. Apolipoprotein D is elevated in oligodendrocytes in the peri-infarct region after experimental stroke: influence of enriched environment. J. Cereb. Blood Flow Metab. 28 (2008) 551-562
30. Ruscher K., Johannesson E., Brugiere E., Erickson A., Rickhag M., and Wieloch T. Enriched environment reduces apolipoprotein E (ApoE) in reactive astrocytes and attenuates inflammation of the peri-infarct tissue after experimental stroke. J. Cereb. Blood Flow Metab. 29 (2009) 1796-1805
31. Schneider A., Kuhn H.G., and Schabitz W.R. A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4 (2005) 1753-1757
32. Sofroniew M.V. Reactive astrocytes in neural repair and protection. Neuroscientist 11 (2005) 400-407
33. STAIRS. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
34. Stevens J.R., Denney D., and Szot P. Kindling with clozapine: behavioral and molecular consequences. Epilepsy Res. 26 (1996) 295-304
35. Stevens J.R., Denney D., and Szot P. Sensitization with clozapine: beyond the dopamine hypothesis. Biol. Psychiatry 42 (1997) 771-780
36. Suresh S., Yan Z., Patel R.C., Patel Y.C., and Patel S.C. Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D. J. Neurochem. 70 (1998) 242-251
37. Terrisse L., Poirier J., Bertrand P., Merched A., Visvikis S., Siest G., Milne R., and Rassart E. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J. Neurochem. 71 (1998) 1643-1650
38. Thomas E.A., and Yao J.K. Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. Schizophr. Res. 89 (2007) 147-153
39. Thomas E.A., Danielson P.E., Nelson P.A., Pribyl T.M., Hilbush B.S., Hasel K.W., and Sutcliffe J.G. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J. Neurochem. 76 (2001) 789-796
40. Thomas E.A., Dean B., Pavey G., and Sutcliffe J.G. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4066-4071
41. Thomas E.A., George R.C., Danielson P.E., Nelson P.A., Warren A.J., Lo D., and Sutcliffe J.G. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol. Psychiatry 8 (2003) 983-993
42. Thomas E.A., Laws S.M., Sutcliffe J.G., Harper C., Dean B., McClean C., Masters C., Lautenschlager N., Gandy S.E., and Martins R.N. Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype. Biol. Psychiatry 54 (2003) 136-141
43. Vogt M., and Skerra A. Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. J. Mol. Recognit. 14 (2001) 79-86
44. Weigmann H., Hartter S., Fischer V., Dahmen N., and Hiemke C. Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur. Neuropsychopharmacol. 9 (1999) 253-256
45. Wieloch T., and Nikolich K. Mechanisms of neural plasticity following brain injury. Curr. Opin. Neurobiol. 16 (2006) 258-264
46. Yao J.K., Thomas E.A., Reddy R.D., and Keshavan M.S. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr. Res. 72 (2005) 259-266
47. Yazici K.M., Erbas T., and Yazici A.H. The effect of clozapine on glucose metabolism. Exp. Clin. Endocrinol. Diabetes 106 (1998) 475-477
48. Zhao C.S., Puurunen K., Schallert T., Sivenius J., and Jolkkonen J. Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury. Behav. Brain Res. 158 (2005) 211-220